Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.55 |
| ▸ | HTR4 | Q13639 | 4/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 3/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.44 |
| ▸ | MERTK | Q12866 | 3/20 | 0.44 |
| ▸ | AXL | P30530 | 2/20 | 0.44 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAS6 | Q14393 | 2/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | TTK | P33981 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366388 | 0.84 | POLB (0.63) | POLBCYP3A4SMN1; SMN2 | |
| SCHEMBL1364923 | 0.82 | DGAT1 (0.53) | DGAT1GABRA5FLT3TYRO3MERTK | |
| SCHEMBL14094525 | 0.82 | DGAT1 (0.53) | DGAT1CRHR1CRHR2POLBSMN1; SMN2 | |
| SCHEMBL1366822 | 0.80 | DRD4 (0.60) | DGAT1POLBSMN1; SMN2 | |
| SCHEMBL1367559 | 0.79 | DGAT1 (0.51) | DGAT1HTR4GABRA5FLT3TYRO3 | |
| SCHEMBL2074161 | 0.79 | HPGDS (0.67) | HTR4GABRA5RIPK2HPGDSTTK | |
| SCHEMBL4406616 | 0.79 | KDM4E (0.58) | SMN1; SMN2 | |
| SCHEMBL1364239 | 0.78 | DGAT1 (0.48) | DGAT1SMN1; SMN2 | |
| SCHEMBL1367494 | 0.73 | SLC6A12 (0.62) | POLBCYP3A4 | |
| SCHEMBL1366693 | 0.72 | PARP1 (0.49) | HTR4POLBSMN1; SMN2HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | CYP11B2, CYP11B1, LTC4S | DGAT1 1566/4885HTR4 947/4885GABRA5 1644/4885 |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | DGAT1 1566/4885HTR4 947/4885GABRA5 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.